Investigation Commenced Against Viatris Inc. Over Alleged Securities Law Violations
New York, NY – April 2, 2025 – Levi & Korsinsky, a leading securities law firm, notifies investors that it has commenced an investigation of Viatris Inc. (NASDAQ: VTRS) over possible violations of federal securities laws. The investigation concerns whether Viatris and certain of its officers or directors violated securities laws in connection with the Company’s fourth quarter and full year 2024 financial results.
Background
On February 27, 2025, Viatris issued a press release reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics. The Company reported GAAP net sales of $3.5 billion for the fourth quarter, below the consensus estimate of $3.6 billion. The Company also reported GAAP diluted earnings per share of $0.78 for the fourth quarter, below the consensus estimate of $0.82.
Investigation Details
Levi & Korsinsky’s investigation focuses on whether Viatris and certain of its executives and directors made false and/or misleading statements and/or failed to disclose important information to investors. Specifically, the investigation concerns whether the Company and its executives and directors:
- Provided false or misleading information regarding the Company’s financial condition and prospects;
- Failed to disclose material information regarding risks and uncertainties;
- Engaged in improper accounting practices or failed to maintain adequate financial controls;
Impact on Individual Investors
The investigation of Viatris may have significant implications for individual investors. If the investigation uncovers evidence of securities law violations, Viatris’ stock price could decline, potentially resulting in significant losses for investors. Additionally, if the investigation leads to regulatory action or litigation, investors may be entitled to recover damages.
Impact on the World
The investigation of Viatris also has potential implications for the broader business community. If the investigation uncovers evidence of securities law violations, it could serve as a warning to other companies and executives to ensure that they are transparent and truthful in their reporting. Additionally, if the investigation leads to regulatory action or litigation, it could potentially lead to increased scrutiny and regulation of the pharmaceutical industry.
Conclusion
The investigation of Viatris by Levi & Korsinsky highlights the importance of transparency and truthfulness in corporate reporting. Investors rely on accurate information when making investment decisions, and companies have a fiduciary duty to provide that information. If you are a Viatris investor and believe that you have suffered losses due to the Company’s alleged securities law violations, you may be entitled to recover damages. To learn more about the investigation and your potential legal rights, please contact Levi & Korsinsky at 212-363-7500 or via email at [email protected].
The investigation also serves as a reminder to all investors to carefully evaluate the information provided by companies and to be vigilant for potential securities law violations. By staying informed and taking action when necessary, investors can help protect themselves and the broader investment community.
